Personalis shares rose after the company received Medicare coverage for its NeXT Personal molecular residual disease test for surveillance of patients with Stage I to III non-small cell lung cancer.
Investing.com -- Personalis Inc (NASDAQ:PSNL) stock jumped 9.3% Tuesday after the precision oncology company announced ...
Personalis, Inc. , a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular residual disease (MRD) test for surveillance of ...
Personalis, Inc. PSNL stock is up in Tuesday’s premarket session after the company received Medicare coverage for its NeXT ...
Asianet Newsable on MSN
Why Personalis stock is rising: Medicare covers lung cancer MRD test
Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with ...
Q4 2025 Earnings Call February 10, 2026 6:45 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results